Services Overview

We act as your agent, representative, interim or mentor/coach. We can set up your company in Japan. We are dedicated to making your commercial success real!

We supply the market intelligence you need to be successful in Japan!

We connect you with the right Japanese companies within Biopharma, ATMP, CGT, Regenerative Medicine, Pharmaceuticals, Combination Devices, IVD’s, Universities and distributors. The right mix you need among: Trade Shows, KOLs, customers, partners, distributors . . .

A handshake under the Rising Sun of Japan.

Biosector = Commercialization in Japan

Preparation and reports – What you need to know!

We produce your feasibility studies and all other types of reports that you need to unlock your commercial pathway into Japan’s Pharmaceutical Industry. We help pave every step of your commercialization process.

Download for free:

You need: fast, accurate and actionable reports, feasibility studies, target lists and analysis to be able to draw up the best strategies.

We supply: just that!

By partnering with Biosector, you get the upper hand!

Market Entry: Seamless Integration and Strategic Positioning

Your success in Japan requires the following keys:

  1. Budget
  2. Cultural competence
  3. Clear goals
  4. Strategic approach
  5. Feet on the ground
  6. Long term mindset
  7. Patience
  8. Consistency


We make sure you are moving as fast as possible and that your expectations are aligned with those of your future clients and partners’ in Japan.

Market Expansion: Optimizing Your New Commercial Opportunities and Accelerating Growth

Expanding your footprint in Japan is crucial. Accelerating your growth successfully equals long-term success. You need competence and excellence: we supply! You need to optimize your new avenues for growth – we support you! We assist you in making sure of your new market segments and their strategies.

Leveraging your opportunities through our extensive industry connections is a valuable shortcut.

With Biosector, you have the advantage that only comes with exceptional professionals. Every step of the way.

About Stefan Sandström 

CEO of Biosector Ltd. Residence

Residence: Based in Metropolitan Tokyo since 2007.

Unique Perspective: Science and business.

Education: Medicine and chemical engineering.

Leadership: Successfully led multiple industrial companies as CEO.

Accreditations: Accredited business consultant via  German RKW.

Collaborations: Japanese partner to notable entities:  SPECTARIS and Kalms Consulting.

Recognitions: Appointed as an expert on conducting business in Japan by the EU-Japan Centre for Industrial Cooperation.

Track Record: Three decades of experience in international and cross-border business development, achieving first sales.

Passion: Kendo (martial art) with the rank of 6 dan.

Testimonials/Cases

Dan Spacie

CEO of MAP Patient Access, UK

”I have worked with Stefan Sandström outside of Biosector for over a year and will continue to work with him in Biosector. This is an exceptionally highly skilled partner, walking the extra mile and having made all the difference for building our traction in Japan.”

Anne-Kathrin Schmalz

Senior Manager Foreign Trade and Export Promotion

”Mr Sandström delivered an amazing seminar for our members in Sep 2021. He combined extensive specialist knowledge of the Japanese bio and laboratory market and how to bridge cultural differences. ”

Tony White

“Biosector’s business intelligence has helped me identify investment opportunities I would never have discovered. They deliver incisive analysis applying the Pareto Principle, allowing me to make fast decisions and save huge amounts of time. A great help for guiding the next steps forward.” – Tony White, founder of BioPhorum and angel investor

Blog

Illustration showing the global impact of Most Favoured Nation drug pricing policies, featuring the US Capitol, Japan, pharmaceutical pricing scales, global market connections, and declining pricing graphs symbolizing pressure on global pharma economics and innovation.
The global pharmaceutical pricing system may be approaching one of its most important structural shifts in decades. And if Japan begins moving toward a US-style “Most Favoured Nation” pricing logic through Chuikyo discussions, the consequences will extend far beyond Tokyo. The US MFN model was born […]
Editorial illustration showing Shionogi’s logo on a central corporate tower above a map of Japan, with global connection lines to the United States and Europe and strategic blocks labeled Qpex, JT Pharma, Torii, Akros, and RADICAVA.
Is Shionogi going global as a pharmaceutical company from Japan, or simply buying growth while its HIV royalty engine still runs strong? That is now a serious question. For years, Shionogi was easy to place in the mental map of Japanese pharma: infectious diseases, antibiotics, influenza, […]
Daiichi Sankyo is no longer best understood as a successful Japanese pharma company with a strong oncology franchise. It is executing a deliberate corporate conversion into an oncology-centred platform company, built around proprietary ADC technology, globalised development and commercialisation capabilities, and a strong willingness to reshape […]
Stylized wide illustration of Japan as a connected bioeconomy ecosystem, with biopharma, diagnostics, data, biomanufacturing, and global collaboration hubs linked through clean pathways around a central innovation hub.
Japan wants biotechnology to become a larger part of its economy by 2030. That is the core of Japan’s Bioeconomy Strategy. Let’s look past the government language and interpret this as a market signal. Japan is showing where it wants more innovation, more industrial capability, and […]
Editorial illustration showing complex healthcare data, regulatory, and localization inputs being streamlined through a Japan-themed gateway into clear eCOA/ePRO digital tools used by a doctor and patient.
Japan is one of the world’s most demanding healthcare markets. It is also one of the most attractive for digital health companies that can meet its expectations for precision, reliability, data integrity, and user experience. If you are developing electronic Clinical Outcome Assessment (eCOA) and electronic […]

Please feel warmly welcome to contact us:

email: info@biosector.jp
phone: +81 80-3404-8431

Address: Yokohama Landmark Tower, 20th Floor, 2-2-1 Minatomirai, Nishi-ku, 〒220-8120,

Yokohama, JAPAN

Deliveries: Kosugaya 1-20-6-202, Sakae-ku, 〒247-0007, Yokohama, JAPAN